Best-in-Class next generation anti infectives

Unique MoA based on natural defense peptides in humans and rapid eradication of multi-drug resistant bacteria /Anti-biofilm capabilities and highly robust against resistancy development

Efficacy and safety demonstrated preclinically for multiple MDR bacteria /Safety confirmed in animals

  • Antimicrobial compounds

  • Bacteria

  • Human
  • Veterinary

Development stage:
  • Research
  • Development

  • Company

  • License, Co-develop, Joint Venture

Prefferably investor or codevelopment/lisence partner with infectious diseases expertise or background

Start-up developing anti-infectives with a novel mechanism of action

Suitable for human and veterinary applications /Applicable to broad and multi-billion $ markets: Topical & dermal infections, implant infections, MRSA, urinary tract infections, lyme disease, sepsis, respiratory, …)

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!